TIPS for Adults Without Cirrhosis With Chronic Mesenteric Venous Thrombosis and EHPVO Refractory to Standard‐of‐Care Therapy. Issue 5 (8th July 2021)

• Record Type: Journal Article
• Authors: Knight, Gabriel M.; Clark, Jeffrey; Boike, Justin R.; Maddur, Haripriya; Ganger, Daniel R.; Talwar, Abhinav; Riaz, Ahsun; Desai, Kush; Mouli, Samdeep; Hohlastos, Elias; Garcia Pagan, Juan‐Carlos; Gabr, Ahmed; Stein, Brady; Lewandowski, Robert; Thornburg, Bartley; Salem, Riad
• Is Part Of: Hepatology. Volume 74:Issue 5(2021)
• Page Start: 2735
• Page End: 2744
• Publication Date: 2021-07-08
• Subjects: Heart -- Diseases -- Nursing -- Periodicals; Lungs -- Diseases -- Nursing -- Periodicals; Intensive care nursing -- Periodicals; Foie -- Maladies -- Périodiques; 616.362
• DOI: 10.1002/hep.31915
• Languages: English
• ISSNs: 0270-9139

Abstract

Abstract : Background and Aims: Extrahepatic portal vein occlusion (EHPVO) from portal vein thrombosis is a rare condition associated with substantial morbidity and mortality. The purpose of this study is to investigate the efficacy of transjugular intrahepatic portosystemic shunts (TIPS) for the treatment of chronic EHPVO, cavernomatosis, and mesenteric venous thrombosis in adults without cirrhosis who are refractory to standard‐of‐care therapy. Approach and Results: Thirty‐nine patients with chronic EHPVO received TIPS. Laboratory parameters and follow‐up were assessed at 1, 3, 6, 12, and 24 months, and every 6 months thereafter. Two hepatologists adjudicated symptom improvement attributable to mesenteric thrombosis and EHPVO before/after TIPS. Kaplan‐Meier was used to assess primary and overall TIPS patency, assessing procedural success. Adverse events, radiation exposure, hospital length‐of‐stay and patency were recorded. Cavernoma was present in 100%, with TIPS being successful in all cases using splenic, mesenteric, and transhepatic approaches. Symptom improvement was noted in 26 of 30 (87%) at 6‐month follow‐up. Twelve patients (31%) experienced TIPS thrombosis. There were no significant long‐term laboratory adverse events or deaths. At 36 months, freedom from primary TIPS thrombosis was 63%; following secondary interventions, overall patency was increased to 81%. Conclusions: TIPS in chronic, noncirrhotic EHPVO with cavernomas and mesenteric venous thrombosis is technically feasible and does not adversely affect liver function. Most patients demonstrate subjective and objective benefit from TIPS. Improvement in patency rates are needed with proper timing of adjuvant anticoagulation.